One way to level the playing field is to offer the public plan through an administered market system.
Insurers and employers, however, are leery about competing with a subsidized public program. They fear that healthy consumers eventually would opt for the less-expensive public plan and further the shift to a government-run healthcare system.
PROVIDING CHOICE
Rep. Pete Stark (D-Calif.), chairman of the House Ways & Means Health subcommittee, is a lead proponent of the public plan option, maintaining that it would help trim spending on healthcare and make coverage more affordable.
Congressional Democrats also want to establish a government-run Medicare drug plan that would compete with private plans offering Part D pharmaceutical benefits. Senate Majority Whip Richard Durbin (D-Ill.) has joined with House leaders in sponsoring legislation that permits Medicare to operate a low-cost plan that would benefit from government negotiated drug prices. The stated aim of consumer advocates is to force out private plans and end the competitive approach to providing the Medicare drug benefit.
Insurers, hospitals and payers fear that a government-sponsored plan would have authority to set negotiated prices for providers and thus could reduce its costs much more than private plans. Similar to the Medicare program, the public plan also might not have to account for administrative costs or maintain reserves, giving it important advantages over private insurers.
One way to level the playing field is to offer the public plan through an administered market system. The federal government or national board would set parameters for benefits and premiums, and insurers would bid on the product. That approach, similar to the federal health insurance program for government employees, would be very different from the government-run plan envisioned by most Democrats.
There is agreement that any public plan option should be linked to an individual mandate on coverage. Stark said at a December briefing that to have a reasonably priced plan, "everyone has to be in the pool and pay." Insurers similarly acknowledge that universal coverage is necessary to eliminate exclusions for pre-existing conditions.
Congressional Republicans say they will fight any proposal that puts everyone in a Medicare-type program, which would evolve into a "super-HMO" able to dictate care.
Democrats maintain that the public option is critical to any agreement on health reform. Rep. Henry Waxman (D-Calif.), chairman of the House Energy & Commerce Committee, described the public plan as an alternative to a single-payer system, and that increased "creative tension" between public and private plans can be beneficial. But, he noted, financing and coverage are critical.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More